Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca boosted by Crestor demand

AstraZeneca boosted by Crestor demand

28th March 2006

The UK-listed pharmaceutical giant AstraZeneca has been lifted by a surge in demand for its heart drug Crestor.

A study published in the US earlier this month showed that Crestor could help reduce the plaque that builds up in the arteries leading to the heart, known as Atherosclerosis.

This build-up can lead to blood clots and strokes.

The so-called Asteroid study found that a 40mg dose of Crestor taken once-a-day for two years could benefit people with coronary artery disease.

Since the study was released sales of the drug have increased, giving Crestor an 8.2 per cent share of the new prescriptions market in the US last week. This was a rise of 0.6 per cent on the previous week.

“Asteroid was good news both for patients and Crestor sales, as indicated by the latest topline US new and total prescriptions figures,” AstraZeneca spokesman Steve Brown told the Reuters news agency.

Atherosclerosis occurs when a build-up of cholesterol, inflammatory cells and fibrous tissue forms areas in the artery wall called plaques.

These plaques can rupture, blocking the flow of blood to the heart or the brain, causing heart attacks and strokes.

track© Adfero Ltd

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.